MoonLake Immunotherapeutics Class A Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for MLTX, updated each market day.
MLTX AI Sentiment
AI predicts MoonLake Immunotherapeutics Class A Ordinary Shares stock is likely to decrease over the next 10 market days.
Prediction date: July 2, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About MoonLake Immunotherapeutics Class A Ordinary Shares
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Sector
Exchange
Market Cap
$1,490,488,083
Cap Tier
Employees
130
Headquarters
ZUG, V8
Listed Since
April 6, 2022
Website
MLTX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MLTX Volatility
MoonLake Immunotherapeutics Class A Ordinary Shares has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
